William Stilley the CEO of Adial Pharmaceuticals, a publicly traded company specializing in medicines that fight addiction joins eHealth Radio and the Addiction & Health News Channels.

The company’s first drug addresses those with a genetic predisposition to alcohol use disorder and is about to enter into a phase 3 clinical trial. It is estimated that alcohol is the leading cause of death globally among 15-49 year olds.

What is currently being done to fight and deal with alcohol addiction?

What is Adial Pharmaceutical’s solution to the alcohol addiction problem? Specifically how does your drug work?

How does someone get tested for a genetic predisposition? Can they get involved in your clinical trial?

Where can interested parties find out more and follow the advancement of your clinical trial?

Assuming you are successful in your trial, what’s next and when do you think this solution will be available?

William B. Stilley has served as the Chief Executive Officer since December 2010. Prior to joining Adial Pharmaceuticals, he was the Vice President, Business Development & Strategic Projects at Clinical Data, Inc. (NASDQ CLDA), where he worked on licensing and M&A transactions and was involved in management of Phase 3 clinical trials, production of Viibryd® for initial commercial launch of the product, and sourcing drug product and drug substance for the Phase 3 clinical trials of the Company’s vasodilator drug for myocardial stress imaging. Before entering the business community, Mr. Stilley served as Captain in the U.S. Marine Corps.

Mr. Stilley has an MBA with honors from the Darden School of Business and a B.S. in Commerce/Marketing from the McIntire School of Commerce at the University of Virginia. Until recently, he guest lectured at the Darden School of Business, two courses on the management of life science companies. He currently serves on the Board of Virginia BIO, the statewide biotechnology organization. He also holds a patent for Stedivaze®, which is currently in Phase 3 clinical development.